Cancer clinical trials in the region Bretagne

262 currently recruiting clinical trials
Region Bretagne

Phase 2 Liver and bile duct cancer #NCT06254248 #2024-514400-14-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Transplant
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 2 Liver and bile duct cancer #NCT07122089
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Localized Locally Advanced
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
2 recruiting sites
Centre Eugène Marquis
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05128825
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2 Breast cancer #NCT07007559
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
4 recruiting sites
ALX Oncologie Inc
Phase 2 Breast cancer #NCT06680596 #2024-515349-41-00
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC) Hormone therapy
34 recruiting sites
UNICANCER
Phase 2 Colon cancer Rectal cancer #NCT04659382
Required disease stage
Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
6 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04678362 #2024-516182-37-01
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma Other
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
10 recruiting sites
Centre François Baclesse
Phase 2 Breast cancer #NCT05955170 #2022-500743-20-00
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
9 recruiting sites
Institut Curie
Phase 2 Pancreas cancer Sarcoma and GIST #NCT05732831 #2022-502645-99-00
Required histologic types
Bone sarcoma Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Tango Therapeutics
Phase 2 Head and neck cancer #NCT05582122
Required histologic types
Oropharynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Radiochemotherapy
Required P16 statuses
P16 Positive
10 recruiting sites
UNICANCER